london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Sickle cell retinopathy- 2 case-reports

Poster Details

First Author: A.Cabugueira PORTUGAL

Co Author(s):    B. Borges   V. Lemos   M. Cardoso   R. Flores   M. Marques      0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To describe two cases of sickle cell retinopathy with different therapeutic approaches. Hemoglobinopathies are a group of inherited disorders characterized by quantitative or qualitative malformations of hemoglobin. Sickle cell hemoglobinopathies result from an abnormality in the beta chain of the hemoglobin molecule.

Setting:

Patients with sickle cell disease are susceptible to develop peripheral retinal neovascularization, also called sea fans, vitreous hemorrhage and retinal detachments, which are the main causes of vision loss.

Methods:

The authors present two cases of sickle cell retinopathy with different therapeutic approaches. Visual acuity, intraocular pressure, biomicroscopy, fundoscopy, retinography, angiography and optical coherence tomography were performed.

Results:

A 39 years old men, with sickle cell disease, SC genotype and history of miodesopsias in the left eye (LE). On examination he was 20/20 of visual acuity and a stage III C in the right eye (RE) and stage IV of retinopathy in LE on fundoscopy/ angiography. Peripheral retinal scatter photocoagulation was performed. A 22 years old woman, without any ophthalmologic symptoms was 20/20 visual acuity. On fundoscopy/angiography, she was a retinopathy sickle cell, stage I/II RE and stage III C in LE. We decided to follow up the natural course of the disease without photocoagulation.

Conclusions:

Sickle cell retinopathy is the most important ophthalmologic feature of this disease. It`s characterized by a wide spectrum of manifestations that require follow up, to choose the best therapeutic options available.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy